Entera Bio Ltd (ENTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Entera Bio Ltd (ENTX) has a cash flow conversion efficiency ratio of -0.180x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.74 Million) by net assets ($15.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Entera Bio Ltd (ENTX) total market value for the company's overall valuation and market capitalisation.
Entera Bio Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Entera Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entera Bio Ltd ranked by their cash flow conversion efficiency. Explore Entera Bio Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
0.065x |
|
Solutions 30 SE
F:30L3
|
-0.234x |
|
Angkor Resources Corp
V:ANK
|
-0.718x |
|
POLARIS WORKS Inc
KQ:123010
|
0.019x |
|
Genesem Inc
KQ:217190
|
-0.007x |
|
Aemulus Holdings Bhd
KLSE:0181
|
-0.202x |
|
Urbana Corporation
TO:URB
|
-0.008x |
|
Ersan Alisveris Hizmetleri & Gida Sanayi Ticaret AS
IS:KIMMR
|
0.093x |
Annual Cash Flow Conversion Efficiency for Entera Bio Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Entera Bio Ltd from 2015 to 2024. View Entera Bio Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.08 Million | $-6.82 Million | -0.844x | -19.89% |
| 2023-12-31 | $10.39 Million | $-7.31 Million | -0.704x | +33.81% |
| 2022-12-31 | $11.75 Million | $-12.50 Million | -1.063x | -164.76% |
| 2021-12-31 | $22.57 Million | $-9.06 Million | -0.402x | +71.43% |
| 2020-12-31 | $7.51 Million | $-10.56 Million | -1.406x | -87.86% |
| 2019-12-31 | $11.92 Million | $-8.92 Million | -0.748x | +22.73% |
| 2018-12-31 | $10.12 Million | $-9.80 Million | -0.968x | -775.20% |
| 2017-12-31 | $-31.56 Million | $-4.53 Million | 0.143x | +15.24% |
| 2016-12-31 | $-25.25 Million | $-3.14 Million | 0.124x | -8.53% |
| 2015-12-31 | $-25.69 Million | $-3.50 Million | 0.136x | -- |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more